Checkpoint Inhibition in Addition to Dabrafenib/Trametinib for BRAF V600E -Mutated Anaplastic Thyroid Carcinoma

曲美替尼 达布拉芬尼 医学 内科学 肿瘤科 癌症研究 甲状腺癌 MEK抑制剂 甲状腺间变性癌 威罗菲尼 甲状腺 黑色素瘤 甲状腺癌 MAPK/ERK通路 磷酸化 遗传学 转移性黑色素瘤 生物
作者
Sarah Hamidi,Priyanka Iyer,Ramona Dadu,Maria Gule-Monroe,Anastasios Maniakas,Mark Zafereo,Jennifer Wang,Naifa L. Busaidy,Maria E. Cabanillas
出处
期刊:Thyroid [Mary Ann Liebert, Inc.]
卷期号:34 (3): 336-346 被引量:72
标识
DOI:10.1089/thy.2023.0573
摘要

Background: The dabrafenib plus trametinib combination (DT) has revolutionized the treatment of BRAF V600E -mutated anaplastic thyroid carcinoma (BRAFm-ATC). However, patients eventually develop resistance and progress. Single-agent anti-PD-1 inhibitor spartalizumab has shown a median overall survival (mOS) of 5.9 months. Combination of immunotherapy with BRAF/MEK inhibitors (BRAF/MEKi) seems to improve outcomes compared with BRAF/MEKi alone, although no direct comparison is available. BRAF-targeted therapy before surgery (neoadjuvant approach) has also shown improvement in survival. We studied the efficacy and safety of DT plus pembrolizumab (DTP) compared with current standard-of-care DT alone as an initial treatment, as well as in the neoadjuvant setting. Methods: Retrospective single-center study of patients with BRAFm-ATC treated with first-line BRAF-directed therapy between January 2014 and March 2023. Three groups were evaluated: DT, DTP (pembrolizumab added upfront or at progression), and neoadjuvant (DT before surgery, and pembrolizumab added before or after surgery). The primary endpoint was mOS between DT and DTP. Secondary endpoints included median progression-free survival (mPFS) and response rate with DT versus DTP as initial treatments, and the exploratory endpoint was mOS in the neoadjuvant group. Results: Seventy-one patients were included in the primary analysis: n = 23 in DT and n = 48 in DTP. Baseline demographics were similar between groups, including the presence of metastatic disease at start of treatment ( p = 0.427) and prior treatments with surgery ( p = 0.864) and radiation ( p = 0.678). mOS was significantly longer with DTP (17.0 months [confidence interval CI, 11.9–22.1]) compared with DT alone (9.0 months [CI, 4.5–13.5]), p = 0.037. mPFS was also significantly improved with DTP as the initial treatment (11.0 months [CI, 7.0–15.0]) compared with DT alone (4.0 months [CI, 0.7–7.3]), p = 0.049. Twenty-three patients were in the exploratory neoadjuvant group, where mOS was the longest (63.0 months [CI, 15.5–110.5]). No grade 5 adverse events (AEs) occurred in all three cohorts, and 32.4% had immune-related AEs, most frequently hepatitis and colitis. Conclusions: Our results show that in BRAFm-ATC, addition of pembrolizumab to dabrafenib/trametinib may significantly prolong survival. Surgical resection of the primary tumor after initial BRAF-targeted therapy in selected patients may provide further survival benefit. However, conclusions are limited by the retrospective nature of the study. Additional prospective data are needed to confirm this observation.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
杨修发布了新的文献求助10
刚刚
123的应助被哇哈哈哈哈哈采纳,获得10
1秒前
顺顺顺发布了新的文献求助10
1秒前
Lotus发布了新的文献求助10
1秒前
霸波儿奔完成签到,获得积分10
1秒前
1秒前
无聊完成签到,获得积分10
1秒前
红丽阿妹发布了新的文献求助10
1秒前
真实的含羞草完成签到,获得积分10
2秒前
zhouhaoyi发布了新的文献求助10
2秒前
2秒前
Simon完成签到,获得积分10
2秒前
彭于晏的应助被Xhaooo采纳,获得10
2秒前
2秒前
2秒前
2秒前
Rudy_Li发布了新的文献求助10
3秒前
Akim的应助被时尚访曼采纳,获得10
3秒前
三七四十三完成签到,获得积分10
3秒前
白宛筠完成签到,获得积分10
3秒前
3秒前
田様的应助被瓷塲采纳,获得10
4秒前
美少叔叔完成签到 ,获得积分10
4秒前
2Sheep完成签到,获得积分10
4秒前
欧阳慕山完成签到,获得积分10
5秒前
Ttttt发布了新的文献求助10
5秒前
暖阳完成签到 ,获得积分10
5秒前
XUE_122发布了新的文献求助10
5秒前
paddi完成签到,获得积分10
5秒前
朱院完成签到,获得积分10
5秒前
向南完成签到 ,获得积分10
5秒前
5秒前
羊屎蛋完成签到 ,获得积分10
5秒前
王雨然发布了新的文献求助10
6秒前
eF完成签到,获得积分10
6秒前
6秒前
希望天下0贩的0的应助被fortuna采纳,获得10
6秒前
6秒前
机智元菱发布了新的文献求助10
6秒前
顾矜的应助被小健采纳,获得10
6秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
Analyses de reconnaissances de dettes passées devant les échevins d'Ypres (1249-1291) 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8159480
求助须知:如何正确求助?哪些是违规求助? 9554975
关于积分的说明 21723753
捐赠科研通 7749303
什么是DOI,文献DOI怎么找? 3427226
关于科研通互助平台的介绍 2552227
邀请新用户注册赠送积分活动 2471592